Effects of the Addition of Hiltonol (Poly-ICLC) to a SARS-CoV S Protein Vaccine in Lethal SARS-CoV Mouse ModelMannan, a polysaccharide preparation from Saccharomyces cerevisiae, has previously been shown to enhance influenza virus replication in mice by inhibiting host defense collectins. The use...
Poly ICLC (Hiltonol) Low-MW polylysine and carboxymethyl cellulose Poly(I:C) I.v., 0.008–0.45 mg kg−1, qwk, systemic (Phase I and II) 169 AVET Polylysine-modified Tf + adenovirus Plasmid Ex vivo, transfected autologous melanoma cells, cells injected into the patient (Phase I) 170...
A Phase 1 Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in the HVTN706/MOSAICO Study and Remain Without HIV ...
The potential protection of poly-ICLC (Hiltonol) a double stranded RNA (dsRNA) against EBOV infection was assessed with prophylactic and therapeutic administration to wild type and TLR3-negative mice, and in non-human primates (NHPs) by measuring EBOL serum titers, survival extension, and serum...
Effects of the Addition of Hiltonol® (Poly-ICLC) to a SARS-CoV S Protein Vaccine in Lethal SARS-CoV Mouse Modeldoi:10.1016/j.antiviral.2011.03.022Dale L. Barnard and Miles Wandersee and Kevin Bailey and Aaron Smith and Zach Vest and John D. Morrey and Andres M. Salazar...
Hilton B. LevyDr. Dale E. McFarlinJohn Wiley & Sons, Ltd.Annals of NeurologyBever, C.T., McFarland, H.F., Levy, H.B. and McFarlin, D.E. (1988) Cortisol induction by poly ICLC: implications for clinical trials of interferon. Ann. Neurol. 23, 196-199.Bever C J,Mcfarland H F...
Poly ICLC (Hiltonol) Low-MW polylysine and carboxymethyl cellulose Poly(I:C) I.v., 0.008–0.45 mg kg−1, qwk, systemic (Phase I and II) 169 AVET Polylysine-modified Tf + adenovirus Plasmid Ex vivo, transfected autologous melanoma cells, cells injected into the patient (Phase I) 170...